Circio Holding ASA: Requested Conversion of Convertible Bonds

23 Oct 2024 07:48 CEST

Reference is made to Circio Holding ASA's (the "Company") outstanding
convertible bonds as issued to Atlas Special Opportunities, LLC ("Atlas") under
the Investment Agreement entered into between Atlas and the Company in March
2023.

Atlas has, by a notice of conversion, requested conversion of convertible bonds
with a nominal value of NOK 500,000 which, pursuant to the bond terms, are
convertible into 833,333 new shares in the Company at a conversion price of NOK
0.6.

The Company's share capital will accordingly be increased by NOK 499,999.80 by
the issuance of 833,333 new shares upon completion of the conversion by
registration of the share capital increase in the Norwegian Register of Business
Enterprises (Nw.: Foretaksregisteret). Following the conversion, the Company's
total share capital will be NOK 15,211,804.20 divided into 25,353,007 shares,
each with a nominal value of NOK 0.60.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com (erik.wiklund@targovax.com)

Lubor Gaal, CFO
Phone: +34 683343811
Email: lubor.gaal@circio.com (erik.wiklund@targovax.com)

About Circio

Building next generation RNA therapeutics

Circio Holding ASA is a biotechnology company developing novel circular RNA and
immunotherapy medicines.

Circio has established a unique circular RNA (circRNA) platform for genetic
medicine. The proprietary circVec technology is based on a modular genetic
cassette design for efficient biogenesis of multifunctional circRNA from DNA and
viral vectors, which can be deployed in multiple disease settings. The circVec
platform has demonstrated enhanced and more durable protein expression than
classic mRNA vector systems, and has the potential to become the new gold
-standard for DNA and virus-based therapeutics in the future. The circRNA R&D
activities are being conducted by the wholly owned subsidiary Circio AB based at
the Karolinska Institute in Stockholm, Sweden.

In addition, Circio is continuing to develop its legacy oncology program, TG01,
targeting KRAS driver mutations. TG01 is currently being tested in clinical
trials which are being run through academic collaborative networks, supported by
prestigious research grants from Innovation Norway and the Norwegian Research
Council.

More information:
Access the news on Oslo Bors NewsWeb site